200 related articles for article (PubMed ID: 33399841)
1. Bisphosphonates for Postmenopausal Osteoporosis.
Ensrud KE
JAMA; 2021 Jan; 325(1):96. PubMed ID: 33399841
[No Abstract] [Full Text] [Related]
2. Bisphosphonates in osteoporosis: NICE and easy?
Harvey NC; McCloskey E; Kanis JA; Compston J; Cooper C
Lancet; 2017 Nov; 390(10109):2243-2244. PubMed ID: 29165263
[No Abstract] [Full Text] [Related]
3. Ocular side effects of bisphosphonates: A case report and literature review.
McKague M; Jorgenson D; Buxton KA
Can Fam Physician; 2010 Oct; 56(10):1015-7. PubMed ID: 20944044
[No Abstract] [Full Text] [Related]
4. Drug holidays in women treated for postmenopausal osteoporosis.
McClung MR
Menopause; 2018 Oct; 25(10):1152-1154. PubMed ID: 30044265
[TBL] [Abstract][Full Text] [Related]
5. Zoledronic acid: new indication. No therapeutic advantage in postmenopausal osteoporosis.
Prescrire Int; 2008 Aug; 17(96):143. PubMed ID: 19480098
[TBL] [Abstract][Full Text] [Related]
6. Bisphosphonates for osteoporosis.
Towner S; Burton DS
N Engl J Med; 2011 Feb; 364(6):583; author reply 583-4. PubMed ID: 21306266
[No Abstract] [Full Text] [Related]
7. [Post hip fracture care].
Tandjung R; Rosemann T
Praxis (Bern 1994); 2011 Jul; 100(15):917-21. PubMed ID: 21792807
[TBL] [Abstract][Full Text] [Related]
8. Efficacy and safety of denosumab compared to bisphosphonates in improving bone strength in postmenopausal osteoporosis: a systematic review.
Chandran T; Venkatachalam I
Singapore Med J; 2019 Jul; 60(7):364-378. PubMed ID: 30854568
[TBL] [Abstract][Full Text] [Related]
9. Bisphosphonates for osteoporosis.
Vis M; Dijkmans BA; Lems WF
N Engl J Med; 2011 Feb; 364(6):582-3; author reply 583-4. PubMed ID: 21306267
[No Abstract] [Full Text] [Related]
10. Bisphosphonates for osteoporosis.
Favus MJ
N Engl J Med; 2010 Nov; 363(21):2027-35. PubMed ID: 21083387
[No Abstract] [Full Text] [Related]
11. Lasofoxifene: new drug. Osteoporosis: no better than raloxifene.
Prescrire Int; 2009 Dec; 18(104):247. PubMed ID: 20020572
[No Abstract] [Full Text] [Related]
12. Ibandronic acid IV: new formulation. Unconvincing evidence.
Prescrire Int; 2008 Feb; 17(93):10. PubMed ID: 18354845
[No Abstract] [Full Text] [Related]
13. [Osteoporosis and bisphosphonates].
Zuber MA
Z Rheumatol; 2007 Dec; 66(8):713-5. PubMed ID: 17955251
[No Abstract] [Full Text] [Related]
14. [Questions and answers about bisphosphonates].
Letonturier P
Presse Med; 2007 Mar; 36(3 Pt 1):440. PubMed ID: 17436449
[No Abstract] [Full Text] [Related]
15. Once-yearly administered intravenous zoledronic acid for postmenopausal osteoporosis.
Woodis CB
Ann Pharmacother; 2008 Jul; 42(7):1085-9. PubMed ID: 18505912
[TBL] [Abstract][Full Text] [Related]
16. Clinical Practice. Postmenopausal Osteoporosis.
Black DM; Rosen CJ
N Engl J Med; 2016 Jan; 374(3):254-62. PubMed ID: 26789873
[TBL] [Abstract][Full Text] [Related]
17. The safety and tolerability profile of therapies for the prevention and treatment of osteoporosis in postmenopausal women.
Komm BS; Morgenstern D; A Yamamoto L; Jenkins SN
Expert Rev Clin Pharmacol; 2015; 8(6):769-84. PubMed ID: 26482902
[TBL] [Abstract][Full Text] [Related]
18. Bisphosphonates and glucocorticoids: effects on bone quality.
Lems WF
Arthritis Rheum; 2007 Nov; 56(11):3518-22. PubMed ID: 17968935
[No Abstract] [Full Text] [Related]
19. [Innovations in the treatment of osteoporosis].
Tsourdi E; Hofbauer LC
Dtsch Med Wochenschr; 2011 Dec; 136(48):2458-60. PubMed ID: 22109575
[No Abstract] [Full Text] [Related]
20. Bisphosphonates and colon cancer.
Lankarani KB
Osteoporos Int; 2013 Mar; 24(3):1139-40. PubMed ID: 22810919
[No Abstract] [Full Text] [Related]
[Next] [New Search]
